Get the Stockscreener App
56.22
1.00%
-0.57
After Hours:
56.22
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $56.22, with a volume of 1.81M.
It is down -1.00% in the last 24 hours and down -4.36% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$56.79
Open:
$56.88
24h Volume:
1.81M
Relative Volume:
0.81
Market Cap:
$8.81B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
59.81
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
+3.48%
1M Performance:
-4.36%
6M Performance:
-8.18%
1Y Performance:
-20.85%
1-Day Range:
$56.02
$57.37
1-Week Range:
$53.89
$57.60
52-Week Range:
$46.01
$80.95
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
56.22 | 8.83B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
BIO-TECHNE Corp Directors Execute Share Sales - TradingView
Using Python tools to backtest Bio Techne Corporation strategiesGDP Growth & Weekly Top Gainers Trade List - Newser
Risk adjusted return profile for Bio Techne Corporation analyzedWeekly Trading Summary & AI Forecast Swing Trade Picks - Newser
Using economic indicators to assess Bio Techne Corporation potentialJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Tools to monitor Bio Techne Corporation recovery probability2025 Price Momentum & Scalable Portfolio Growth Methods - Newser
Leading Biotech Company Bio-Techne Set for Three Major Wall Street Healthcare Conference Presentations - Stock Titan
Applying sector rotation models to Bio Techne Corporation2025 Price Momentum & Weekly High Potential Alerts - Newser
What machine learning models say about Bio Techne CorporationBuy Signal & Reliable Price Breakout Signals - Newser
Is Bio Techne Corporation a candidate for recovery playWeekly Trade Summary & Low Drawdown Investment Strategies - Newser
Applying big data sentiment scoring on Bio Techne Corporation2025 Market Trends & Accurate Buy Signal Alerts - Newser
Published on: 2025-08-27 14:37:47 - Newser
Using Ichimoku Cloud for Bio Techne Corporation technicalsQuarterly Trade Review & Stock Market Timing Techniques - Newser
Advanced analytics toolkit walkthrough for Bio Techne CorporationWeekly Loss Report & Precise Swing Trade Entry Alerts - Newser
Is it time to cut losses on Bio Techne CorporationJuly 2025 Macro Moves & Reliable Price Breakout Signals - Newser
Hong Kong biopharma stocks pull back; Ocumension Bio falls over 15% - AInvest
Bio-Techne Faces NIH & Tariff Uncertainty–Can They Outpace Policy Risks? - Smartkarma
Intraday pattern recognizer results for Bio Techne Corporation2025 Growth vs Value & Weekly Market Pulse Updates - Newser
What momentum shifts mean for Bio Techne CorporationNew Guidance & Community Trade Idea Sharing - Newser
Using flow based indicators on Bio Techne CorporationJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Published on: 2025-08-22 19:42:51 - 더경남뉴스
Bio-Techne Upgrade Amid Sector Challenges: Strong Q2 Performance and Easing Tariffs in China - AInvest
Bio-Techne, 10x Genomics, Lumen, EPAM, and ASGN Shares Are Soaring, What You Need To Know - Yahoo Finance
BIO-TECHNE Corp SEC 10-K Report - TradingView
Citi Upgrades Bio-Techne to Buy from Neutral with $70 Price Target - AInvest
Citigroup upgrades Bio-Techne to Buy with a new PT of $70. - AInvest
Understanding Bio Techne Corporation’s price movementQuarterly Profit Summary & Safe Investment Capital Preservation Plans - Newser
Bio Techne Corporation Stock Flags Risk Zone in Volatility Index2025 Pullback Review & Momentum Based Trading Signals - 더경남뉴스
Bio-Techne Stock: Analyst Estimates & Ratings - Barchart.com
How Bio Techne Corporation stock performs during market volatilityTrade Entry Report & Community Trade Idea Sharing - beatles.ru
What makes Bio Techne Corporation stock price move sharplyJuly 2025 Earnings & Expert Approved Momentum Ideas - 더경남뉴스
Stock Analysis | Bio-Techne OutlookA Stock to Watch with Mixed Signals - AInvest
Bio-Techne: Key Dividend Information and Recent Developments Ahead of Ex-Dividend Date on Aug 18, 2025 - AInvest
Three Companies Trading Ex-Dividend on 8/18/25 - AInvest
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and CNA Financial - Nasdaq
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates - GlobeNewswire Inc.
Bio-Techne's (NASDAQ:TECH) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know - Yahoo Finance
Bio-Techne Corporation shares rise 2.40% intraday as S&P 500, Nasdaq futures hit record highs. - AInvest
Bio-Techne's Q4 2025: Navigating Contradictions in NIH Funding, China Growth, and Revenue Outlook - AInvest
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call - Yahoo Finance
Stock Market Rally: Revvity, Avantor, Azenta, Bio-Techne, Amneal Shares Surge Amid Fed Interest Rate Cut Hopes - AInvest
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - Yahoo Finance
TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty - Yahoo Finance
Bio-Techne Earnings: Fourth-Quarter Results In-Line, but Volatile US Policy Is Hurting End Markets - Morningstar
Bio-Techne Leads Key Proteomic Reagent Markets, but Near-Term Challenges Loom - Morningstar
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls - MSN
Can Bio Techne Corporation disrupt its industryMaximum Leverage Stock Strategy - thegnnews.com
Bio-Techne Corp Q4 Earnings: Revenue Exceeds Estimates at $317M, Adjusted EPS Rises to $0.53, GAAP EPS Misses - AInvest
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $53 to $75 - 富途牛牛
Stocks making big moves yesterday: Bloomin' Brands, Bio-Techne, Snap, Grocery Outlet, and Paramount - Yahoo Finance
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $59 to $65 - 富途牛牛
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):